AUTHORS
Elise A. Chong, MD, Emeline R Chong, BA2, Wei-Ting Hwang, PhD3, Megan K. Jones, MPH4, Kaitlin Kennard, BSN5, Brittany Koch, MPH6, Rachel K. Lundberg, PA-C7, Ellen B. Napier, CRNP8, Allison R. Nelson9, Marco Ruella, MD10, Sandra Susanibar-Adaniya, MD, MS11, Stephen J Schuster, MD12
AFFILIATIONS
1 University of Pennsylvania, Abramson Cancer Center, Philadelphia, Pennsylvania, United States
2 University of Pennsylvania, Abramson Cancer Center, Philadelphia, Pennsylvania, United States
3 University of Pennsylvania, Abramson Cancer Center, Philadelphia, Pennsylvania, United States
4 University of Pennsylvania, Abramson Cancer Center, Philadelphia, Pennsylvania, United States
5 University of Pennsylvania, Abramson Cancer Center, Philadelphia, Pennsylvania, United States
6 University of Pennsylvania, Abramson Cancer Center, Philadelphia, Pennsylvania, United States
7 University of Pennsylvania, Abramson Cancer Center, Philadelphia, Pennsylvania, United States
8 University of Pennsylvania, Abramson Cancer Center, Philadelphia, Pennsylvania, United States
9 University of Pennsylvania, Abramson Cancer Center, Philadelphia, Pennsylvania, United States
10 University of Pennsylvania, Abramson Cancer Center, Philadelphia, Pennsylvania, United States
11 University of Pennsylvania, Abramson Cancer Center, Philadelphia, Pennsylvania, United States
12 University of Pennsylvania, Abramson Cancer Center, Philadelphia, Pennsylvania, United States
ABSTRACT
Background and Significance: Despite the availability of anti-CD19 CAR-T for relapsed/refractory (R/R) large B cell lymphomas (LBCL), many patients have uncontrolled LBCL prior to CAR-T, which is associated with poor outcomes. Moreover, only about 30-40% of patients have long-term remissions after CAR-T, and most relapses after CAR-T occur within the first 6 months due to T cell dysfunction or CD19-negative escape. Epcoritamab, a CD3xCD20 bispecific antibody, has demonstrated activity in LBCL R/R after chemoimmunotherapy (Thieblemont et al. JCO 2023). Administration of epcoritamab pre-and post-CAR-T represents a rational strategy to enhance outcomes through the following complementary mechanisms: 1) pre-apheresis therapy may reduce tumor burden; 2) pre-apheresis epcoritamab may preserve or enhance T-cell functionality for CAR T-cell product manufacturing; 3) sequential CD20 and CD19 targeting may mitigate antigen escape; and, 4) post-CAR T epcoritamab may also promote CAR T-cell re-expansion and persistence (Schuster et al. ASH 2019, Abstract #6).
Study Design and Methods: This open-label, single-center, phase IIa study evaluates epcoritamab administered before and after standard-of-care CD19-directed CAR T-cell therapy in patients with R/R LBCL. Eligible patients have R/R LBCL after ≥1 prior line of therapy with confirmed CD20 expression and are referred for CAR T-cell therapy as standard second or later line of therapy. Key exclusion criteria include primary CNS lymphoma, active autoimmune disease, prior solid organ transplantation, and uncontrolled infection. Up to 31 patients will be enrolled. Unless a prior apheresis product is available, participants will receive 2 cycles of epcoritamab prior to leukapheresis; otherwise, participants receive epcoritamab as bridging therapy. After CAR-T, participants with persistent lymphoma at day 28 post CAR-T assessment may receive epcoritamab for up to 12 additional cycles. Participants will be followed for at least 1 year after CAR-T infusion prior to transitioning to survival follow-up.
The primary objective is to assess the feasibility of epcoritamab as lead-in therapy, defined as the proportion of patients receiving ≥1 dose of epcoritamab who proceed to CAR T-cell infusion. Secondary objectives include safety, response rates, progression-free survival, and overall survival. Exploratory objectives planned include characterization of CAR-T and non-CAR T-cell function before and after exposure to epcoritamab and during CAR T cell therapy via multispectral phenotyping including CAR expression, qPCR for CAR transcripts, and single-cell RNA sequencing. To assess lymphoma target expression, we will determine expression of CD19 and CD20 in tumors by immunohistochemistry and flow cytometry. We will also collect serum for circulating tumor DNA (ctDNA) sequencing and monitoring.
Clinicaltrials.gov: NCT06458439
DISCLOSURES
Elise A. Chong, MD: Genmab - Research Funding; CARGO - Research Funding; Nurix - Research Funding; AstraZeneca - Research Funding; AbbVie - Research Funding; Genentech - Research Funding; AstraZeneca - Consultancy (Includes expert testimony); Genentech - Consultancy (Includes expert testimony); Genmab - Consultancy (Includes expert testimony); ADC Therapeutics - Consultancy (Includes expert testimony); AbbVie - Consultancy (Includes expert testimony)